Ensysce Biosciences Achieves Breakthrough in Overdose Protection Study

Ensysce Biosciences has completed a clinical study on its first pain medication with overdose protection, PF614-MPAR, which successfully reduced opioid delivery when three or more doses are consumed simultaneously. The drug is potentially the first to limit opioid exposure when too many pills are swallowed, protecting against overdose. Ensysce's patented technology MPAR™, which ‘switches off' the active drug release, can limit delivery when excess was consumed. The study is a proof-of-concept for the base MPAR™ technology which could be used to control delivery of many other drug classes where there may be a narrow therapeutic range.